Overview

A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate

Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
0
Participant gender:
All
Summary
This study is designed to provide safety and efficacy data to support the development of CP-690,550 in patients with moderate to severe rheumatoid arthritis on background of methotrexate.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Treatments:
Methotrexate
Tofacitinib
Criteria
Inclusion Criteria:

- Adults with moderate to severe rheumatoid arthritis on a stable dose of methotrexate

Exclusion Criteria:

- Pregnancy, severe acute or chronic medical conditions, including serious infections or
clinically significant laboratory abnormalities.